CHALLENGE
Relapsed and Refractory Acute Myeloid Leukemia (R/R AML) presents a major clinical challenge with poor prognosis, limited therapeutic options, and fragmented data collection across Europe. The lack of standardized biobanking, inconsistent Minimal Residual Disease (MRD) analyses, and the absence of inclusive clinical trial designs hinder advancements in research and equitable patient care.
GOAL
IMPACT-AML aims to establish a unified framework for R/R AML data collection, develop biobanking and MRD standardization, and conduct a Randomized Pragmatic Clinical Trial (RPCT) to evaluate rescue therapies. The project prioritizes inclusivity, targeting underrepresented populations and improving accessibility to high-quality AML care across Europe and beyond.
SOLUTION
The project introduces STREAM, a platform for harmonized data collection, enabling cross-border research. Standard Operating Procedures (SOPs) for biobanking and MRD analysis ensure robust biological sample use. The RPCT assesses low- vs high-intensity therapies, providing actionable insights. Pilot telemedicine projects extend care to underserved regions, driving innovation in equitable AML treatment.
